Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia.

Udd KA, Bujarski S, Wirtschafter E, Spektor TM, Ghermezi M, Rassenti LZ, David ME, Nosrati JD, Rahbari AA, Wang J, Vardanyan S, Harutyunyan NM, Linesch J, Li M, Sanchez E, Chen H, Kipps TJ, Berenson JR.

Target Oncol. 2019 Aug 31. doi: 10.1007/s11523-019-00666-0. [Epub ahead of print]

PMID:
31473933
2.

Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.

Gross Z, Rahbari A, Wirtschafter E, Spektor TM, Udd KA, Bujarski S, Ghermezi M, Nosrati JD, Vidisheva A, Eades B, Cecchi G, Maluso T, Swift R, Berenson JR.

Eur J Haematol. 2018 Jun;100(6):621-623. doi: 10.1111/ejh.13058. Epub 2018 Apr 25.

PMID:
29524348
3.

Monitoring multiple myeloma.

Udd KA, Spektor TM, Berenson JR.

Clin Adv Hematol Oncol. 2017 Dec;15(12):951-961.

PMID:
29315287
4.

Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.

Vidisheva AP, Wang J, Spektor TM, Bitran JD, Lutzky J, Tabbara IA, Ye JZ, Ailawadhi S, Stampleman LV, Steis RG, Moezi MM, Swift RA, Maluso TM, Udd KA, Eshaghian S, Nassir Y, Berenson JR.

Support Care Cancer. 2017 Oct;25(10):3217-3224. doi: 10.1007/s00520-017-3732-6. Epub 2017 Apr 28.

PMID:
28455546
5.

Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects.

Chen H, Li M, Sanchez E, Wang CS, Lee T, Soof CM, Casas CE, Cao J, Xie C, Udd KA, DeCorso K, Tang GY, Spektor TM, Berenson JR.

Mol Cancer Res. 2017 May;15(5):598-609. doi: 10.1158/1541-7786.MCR-16-0293. Epub 2017 Jan 25.

6.

Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.

Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR.

Ann Hematol. 2017 Mar;96(3):449-459. doi: 10.1007/s00277-016-2889-2. Epub 2016 Dec 8.

PMID:
27933373
7.

Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.

Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR.

Ann Hematol. 2017 Mar;96(3):441-448. doi: 10.1007/s00277-016-2888-3. Epub 2016 Dec 2.

PMID:
27913860
8.

Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.

Wang J, Udd KA, Vidisheva A, Swift RA, Spektor TM, Bravin E, Ibrahim E, Treisman J, Masri M, Berenson JR.

Support Care Cancer. 2016 Jul;24(7):3105-10. doi: 10.1007/s00520-016-3126-1. Epub 2016 Feb 23.

PMID:
26902977
9.

Risk of skin cancer in multiple myeloma patients: a retrospective cohort study.

Robinson AA, Wang J, Vardanyan S, Madden EK, Hebroni F, Udd KA, Spektor TM, Nosrati JD, Kitto AZ, Zahab M, Cheema S, Fors DH, Norberg A, Diehl J, Waterman GN, Swift RA, Crowley J, Berenson JR.

Eur J Haematol. 2016 Nov;97(5):439-444. doi: 10.1111/ejh.12748. Epub 2016 Mar 7.

PMID:
26872804

Supplemental Content

Support Center